Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

ENROLLING BY INVITATION

NCT06898541

Coronary Sinus Reducer in Coronary Microvascular Disease

Sponsor: UMC Utrecht

View on ClinicalTrials.gov

Summary

Coronary microvascular dysfunction (CMD) is a common cause of treatment- resistant angina that lacks evidence-based treatment options. The coronary sinus reducer (CSR) is an hourglass-shaped stainless steel mesh, designed to create a controlled narrowing of the coronary sinus (CS). By augmenting CS pressure, CSR implantation was shown to improve myocardial perfusion, potentially providing a novel treatment for patients with CMD. REDUCE CMD is a placebo-controlled study of CSR in 50 patients with CMD. The main study endpoints are the change in coronary flow reserve from baseline to 6 months in the CSR-arm versus the placebo arm, and the difference in number of daily episodes of angina recorded on the ORBITA-app at 6 month follow-up in the CSR-arm versus the placebo arm.

Official title: Impact of the Coronary Sinus Reducer on Coronary Flow Reserve and Symptoms in Patients With Coronary Microvascular Disease

Key Details

Gender

All

Age Range

40 Years - Any

Study Type

INTERVENTIONAL

Enrollment

Start Date

2025-11-20

Completion Date

2028-11-01

Last Updated

2025-12-04

Healthy Volunteers

Conditions

Angina (Stable)Coronary Microvascular Disease

Interventions

DEVICE

Coronary sinus reducer

Implantation of a Coronary Sinus Reducer device

OTHER

Sham CSR procedure

Patients will undergo a complete sham CSR implantation procedure without actual deployment of the CSR.

Inclusion criteria 1. Coronary microvascular dysfunction in the left anterior descending coronary artery (LAD) as expressed by abnormal absolute coronary flow reserve (CFR\<2.5) confirmed during the index study procedure using the continuous thermodilution technique and saline-induced coronary hyperaemia. 2. Angina - Canadian Cardiovascular Society Class II-IV on at least two anti-anginals or maximally tolerated medical therapy if less than two. 3. Patient understands the nature of the procedure and provides written informed consent for the study prior to enrolment. Exclusion criteria 1. Age \< 18 years. 2. Absence of symptoms reported on the ORBITA-app during the 2-week screening period. 3. Presence of hemodynamically significant epicardial stenoses based on both non- hyperaemic pressure ratio (NHPR; iFR≤0.89, or RFR≤0.89, or dFR/dPR≤0.89) or fractional flow reserve (FFR≤0.80) assessments. 4. Prior positive acetylcholine provocation test with respect to epicardial vasospasm following the COVADIS criteria. 5. Mean right atrial pressure ≥15 mmHg 6. Severe pulmonary hypertension. 7. Coronary sinus anatomy not suitable for CSR implantation. 8. Pregnancy or planned pregnancy within the next 12 months. 9. Recent acute coronary syndrome (within 3 months). 10. Recent revascularization with PCI (within 6 months). 11. Severe arrhythmias, including chronic atrial fibrillation with persistent rapid ventricular response (\>100bpm despite medication). 12. Indication for cardiac resynchronization therapy. 13. Severe left ventricular impairment (left ventricular ejection fraction \<35%). 14. NYHA class IV or decompensated heart failure or hospitalization due to heart failure within 90 days before the index procedure. 15. Recent implantation of a permanent pacemaker or defibrillator lead in the right ventricle or atrium (within 90 days before the index procedure). 16. Presence of a pacemaker lead in the coronary sinus. 17. Severe valvular heart disease. 18. History of tricuspid valve replacement or repair. 19. Contra-indication to short term dual antiplatelet therapy or lifelong aspirin treatment. 20. Currently enrolled in another investigational device or drug trial that has not completed the primary endpoint or that clinically interferes with the current study endpoints. 21. Known inability to tolerate contrast medium. 22. Life expectancy \<1 year.

Locations (2)

Maasstad Ziekenhuis

Rotterdam, Netherlands

UMC Utrecht

Utrecht, Netherlands